OBJECTIVES: Screening HIV-infected men for gonorrhoea (GC) and chlamydia (CT) may decrease HIV transmission and reduce the incidence of pelvic inflammatory disease in female partners. This study determined GC/CT testing rates in a clinical HIV cohort before and after 2003 when the US Centers for Disease Control and Prevention issued guidelines for GC/CT screening. METHODS: First GC/CT testing episodes were identified for all men enrolling in a Baltimore HIV clinic from 1999 to 2007. Multivariate Cox and logistic regression were used to assess clinical and demographic factors associated with being tested and with having a positive result. RESULTS: Among 1110 men, the rate of GC/CT testing upon clinic enrollment increased from 4.0% prior to 2003 to 16.5% afterwards, and the rate of ever being tested increased from 34.2% to 49.1% (p<0.001 for both comparisons). Among men with same sex contact, 10% of first testing episodes included extragenital sites. Among the 342 men ever-tested, 5.2% had positive results on first testing. Predictors of testing included enrolling after 2003, younger age, frequent visits and black race. Predictors of a positive test result included CD4 count ≥ 200 cells/mm(3) and younger age. CONCLUSIONS: GC/CT testing rates among men increased substantially after the 2003 guidelines but remain low. Disseminating existing evidence for GC/CT screening and promoting operational interventions to facilitate it are warranted.
OBJECTIVES: Screening HIV-infectedmen for gonorrhoea (GC) and chlamydia (CT) may decrease HIV transmission and reduce the incidence of pelvic inflammatory disease in female partners. This study determined GC/CT testing rates in a clinical HIV cohort before and after 2003 when the US Centers for Disease Control and Prevention issued guidelines for GC/CT screening. METHODS: First GC/CT testing episodes were identified for all men enrolling in a Baltimore HIV clinic from 1999 to 2007. Multivariate Cox and logistic regression were used to assess clinical and demographic factors associated with being tested and with having a positive result. RESULTS: Among 1110 men, the rate of GC/CT testing upon clinic enrollment increased from 4.0% prior to 2003 to 16.5% afterwards, and the rate of ever being tested increased from 34.2% to 49.1% (p<0.001 for both comparisons). Among men with same sex contact, 10% of first testing episodes included extragenital sites. Among the 342 men ever-tested, 5.2% had positive results on first testing. Predictors of testing included enrolling after 2003, younger age, frequent visits and black race. Predictors of a positive test result included CD4 count ≥ 200 cells/mm(3) and younger age. CONCLUSIONS:GC/CT testing rates among men increased substantially after the 2003 guidelines but remain low. Disseminating existing evidence for GC/CT screening and promoting operational interventions to facilitate it are warranted.
Authors: M S Cohen; I F Hoffman; R A Royce; P Kazembe; J R Dyer; C C Daly; D Zimba; P L Vernazza; M Maida; S A Fiscus; J J Eron Journal: Lancet Date: 1997-06-28 Impact factor: 79.321
Authors: M J Wawer; N K Sewankambo; D Serwadda; T C Quinn; L A Paxton; N Kiwanuka; F Wabwire-Mangen; C Li; T Lutalo; F Nalugoda; C A Gaydos; L H Moulton; M O Meehan; S Ahmed; R H Gray Journal: Lancet Date: 1999-02-13 Impact factor: 79.321
Authors: A Kamali; M Quigley; J Nakiyingi; J Kinsman; J Kengeya-Kayondo; R Gopal; A Ojwiya; P Hughes; L M Carpenter; J Whitworth Journal: Lancet Date: 2003-02-22 Impact factor: 79.321
Authors: Rupert Kaul; Joshua Kimani; Nico J Nagelkerke; Karoline Fonck; Elizabeth N Ngugi; Florence Keli; Kelly S MacDonald; Ian W Maclean; Job J Bwayo; Marleen Temmerman; Allan R Ronald; Stephen Moses Journal: JAMA Date: 2004-06-02 Impact factor: 56.272
Authors: H Grosskurth; F Mosha; J Todd; E Mwijarubi; A Klokke; K Senkoro; P Mayaud; J Changalucha; A Nicoll; G ka-Gina Journal: Lancet Date: 1995-08-26 Impact factor: 79.321
Authors: Stephen A Berry; Khalil G Ghanem; Kathleen R Page; Stephen J Gange; Chloe L Thio; Richard D Moore; Kelly A Gebo Journal: Sex Transm Infect Date: 2011-07-11 Impact factor: 3.519
Authors: Susan Tuddenham; Khalil G Ghanem; Kelly A Gebo; Richard D Moore; William Christopher Mathews; Allison Agwu; Kenneth Mayer; Christina Schumacher; Julia Raifman; Stephen A Berry Journal: Sex Transm Infect Date: 2019-04-06 Impact factor: 3.519
Authors: Abigail Norris Turner; Patricia Carr Reese; Melissa Ervin; John A Davis; Karen S Fields; Jose A Bazan Journal: Sex Transm Dis Date: 2013-06 Impact factor: 2.830
Authors: Carole Lunny; Darlene Taylor; Linda Hoang; Tom Wong; Mark Gilbert; Richard Lester; Mel Krajden; Gina Ogilvie Journal: PLoS One Date: 2015-07-13 Impact factor: 3.240
Authors: Ann N Burchell; Vanessa G Allen; Veronika Moravan; Sandra Gardner; Janet Raboud; Darrell H S Tan; Ahmed M Bayoumi; Rupert Kaul; Tony Mazzulli; Frank McGee; Peggy Millson; Robert S Remis; Sean B Rourke Journal: BMC Infect Dis Date: 2013-05-28 Impact factor: 3.090
Authors: Ann N Burchell; Ramandip Grewal; Vanessa G Allen; Sandra L Gardner; Veronika Moravan; Ahmed M Bayoumi; Rupert Kaul; Frank McGee; Margaret Peggy E Millson; Robert S Remis; Janet Raboud; Tony Mazzulli; Sean B Rourke Journal: Sex Transm Infect Date: 2014-09-01 Impact factor: 3.519